Related Experiment Video

Updated: Oct 12, 2025

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis
08:59

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis

Published on: July 16, 2021

2.8K

Deficient neurotransmitter systems and synaptic function in frontotemporal lobar degeneration-Insights into disease

Nadine Huber1, Sonja Korhonen1, Dorit Hoffmann1

  • 1A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, P.O. Box 1627, FI-70211, Kuopio, Finland.

Molecular Psychiatry
|November 20, 2021
PubMed

Insights

Frontotemporal lobar degeneration (FTLD) involves neurotransmitter system deficits. Targeting these systems may offer new therapeutic options for FTLD patients lacking effective treatments.

Area of Science:

  • Neuroscience
  • Neurology
  • Genetics

Background:

  • Frontotemporal lobar degeneration (FTLD) is a fatal neurodegenerative disease with no validated biomarkers or disease-modifying therapies.
  • Current FTLD treatments focus on symptomatic relief using off-label medications.
  • Neurotransmitter system alterations are observed in FTLD patients.

Purpose of the Study:

  • To review current knowledge on neurotransmitter system deficits in FTLD.
  • To explore synaptic dysfunction in common genetic FTLD subtypes (C9orf72, GRN, MAPT).
  • To summarize pharmacological treatments targeting neurotransmitter systems in FTLD.

Main Methods:

  • Literature review of studies on neurotransmitter systems in FTLD.
  • Analysis of data from model systems and patients with genetic FTLD.
  • Examination of current therapeutic strategies targeting neurotransmitter systems.

Main Results:

  • FTLD is associated with changes in glutamatergic, GABAergic, dopaminergic, and serotonergic systems.
  • These neurotransmitter disturbances may explain FTLD symptoms like behavioral changes and hyperorality.
  • Genetic FTLD subtypes (C9orf72, GRN, MAPT) exhibit specific neurotransmitter deficits.

Conclusions:

  • Targeting neurotransmitter systems presents potential therapeutic avenues for FTLD.
  • Further research into neurotransmitter modulation could lead to effective FTLD treatments.
  • Understanding neurotransmitter deficits is crucial for developing subtype-specific FTLD therapies.

More Related Videos

Microtransplantation of Synaptic Membranes to Reactivate Human Synaptic Receptors for Functional Studies10:08

Microtransplantation of Synaptic Membranes to Reactivate Human Synaptic Receptors for Functional Studies

Published on: July 20, 2022

2.2K
Characterizing Histone Post-translational Modification Alterations in Yeast Neurodegenerative Proteinopathy Models08:33

Characterizing Histone Post-translational Modification Alterations in Yeast Neurodegenerative Proteinopathy Models

Published on: March 24, 2019

7.6K

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
820
Long-term Depression01:03

Long-term Depression

Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
2.7K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
736
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
290
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.7K
Role of Neurotransmitters in Memory01:23

Role of Neurotransmitters in Memory

Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
 Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
1.4K